Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | MAOB | P27338 | 8/20 | 0.54 |
| ▸ | HTR6 | P50406 | 2/20 | 0.53 |
| ▸ | IDO1 | P14902 | 2/20 | 0.51 |
| ▸ | AGXT | P21549 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13154286 | 0.86 | RXRA (0.51) | MRGPRX4LMNAL3MBTL1IDO1MAPT | |
| SCHEMBL12524900 | 0.84 | MRGPRX4 (0.62) | MRGPRX4LMNAL3MBTL1MAOBHTR6 | |
| SCHEMBL21086558 | 0.84 | SCN8A (0.48) | MRGPRX4LMNAMAOBIDO1AGXT | |
| SCHEMBL8283224 | 0.83 | FFAR4 (0.56) | MRGPRX4L3MBTL1MAOBHTR6IDO1 | |
| SCHEMBL27521279 | 0.83 | MRGPRX4 (0.63) | MRGPRX4LMNAL3MBTL1MAOBHTR6 | |
| SCHEMBL12301123 | 0.82 | RXRA (0.63) | LMNAL3MBTL1MAOBMAPTMAPK1 | |
| SCHEMBL1406384 | 0.81 | MAOB (0.61) | MRGPRX4LMNAL3MBTL1MAOBHTR6 | |
| SCHEMBL15426843 | 0.81 | FFAR4 (0.65) | MRGPRX4LMNAL3MBTL1MAPTMAPK1 | |
| SCHEMBL11919282 | 0.81 | LMNA (0.64) | MRGPRX4LMNAL3MBTL1MAOBHTR6 | |
| SCHEMBL30631550 | 0.81 | ENPP2 (0.71) | MRGPRX4LMNAL3MBTL1MAOBHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3762364-A1 | PYRROLIDINEAMIDE DERIVATIVES AND USES THEREOF | Sunshine Lake Pharma Co., Ltd. (CN) | 2021-01-13 | — | — | EP | disclosed |
| WO-2019170115-A1 | PYRROLIDINEAMIDE DERIVATIVES AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2019-09-12 | — | — | WO | disclosed |
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. | 2017-08-03 | — | — | US | disclosed |
| US-9273077-B2 | Phosphorus derivatives as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-20150225436-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2015-08-13 | — | — | US | disclosed |
| US-9012462-B2 | Phosphorous derivatives as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-20140364423-A1 | Pyrazinopyrazines and Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. | 2014-12-11 | — | — | US | disclosed |
| US-8846664-B2 | Pyrazinopyrazines and derivatives as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20140066406-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| US-20130225528-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| EP-2168951-A1 | AZOLYLMETHYLENEHYDRAZINE DERIVATIVE AND USE THEREOF | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2010-03-31 | — | — | EP | disclosed |
| US-20080176911-A1 | ACYLAMINOTHIAZOLE DERIVATIVES AND USE THEREOF AS BETA-AMYLOID INHIBITORS | SANOFI-AVENTIS (FR) | 2008-07-24 | — | — | US | disclosed |
| US-20080176911-A1 | ACYLAMINOTHIAZOLE DERIVATIVES AND USE THEREOF AS BETA-AMYLOID INHIBITORS | SANOFI-AVENTIS (FR) | 2008-07-24 | — | — | US | disclosed |
| US-7371770-B2 | Acylaminothiazole derivatives and use thereof as β-amyloid inhibitors | SANOFIAVENTIS (FR) | 2008-05-13 | — | — | US | disclosed |
| US-7371770-B2 | Acylaminothiazole derivatives and use thereof as β-amyloid inhibitors | SANOFIAVENTIS (FR) | 2008-05-13 | — | — | US | disclosed |
| US-20080051436-A1 | Use of Acylaminothiazole Derivatives as Therapeutic Agents | SANOFI-AVENTIS (FR) | 2008-02-28 | — | — | US | disclosed |
| US-20080051436-A1 | Use of Acylaminothiazole Derivatives as Therapeutic Agents | SANOFI-AVENTIS (FR) | 2008-02-28 | — | — | US | disclosed |
| EP-1525193-B1 | ACYLAMINOTHIAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2007-12-26 | — | — | EP | disclosed |
| US-7291636-B2 | Acylaminothiazole derivatives, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2007-11-06 | — | — | US | disclosed |
| US-7291636-B2 | Acylaminothiazole derivatives, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2007-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051436-A1 | Use of Acylaminothiazole Derivatives as Therapeutic Agents | BACE1, BACE2, ATG4A | MRGPRX4 1175/4885LMNA 2746/4885L3MBTL1 1545/4885 |
| US-20140066406-A1 | Phosphorus Derivatives as Kinase Inhibitors | PHKA1, PIK3CA, PHKA2 | MRGPRX4 2325/4885LMNA 3954/4885L3MBTL1 4738/4885 |
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | MRGPRX4 2632/4885LMNA 4121/4885L3MBTL1 4011/4885 |
| US-20150225436-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | MRGPRX4 2508/4885LMNA 4289/4885L3MBTL1 4339/4885 |
| US-20140364423-A1 | Pyrazinopyrazines and Derivatives as Kinase Inhibitors | MAP3K5, MAP3K15, MAP4K2 | MRGPRX4 1229/4885LMNA 4181/4885L3MBTL1 4596/4885 |
| US-20080176911-A1 | ACYLAMINOTHIAZOLE DERIVATIVES AND USE THEREOF AS BETA-AMYLOID INHIBITORS | APP, BACE1, ATG4A | MRGPRX4 2425/4885LMNA 1762/4885L3MBTL1 1751/4885 |
| US-20130225528-A1 | Phosphorus Derivatives as Kinase Inhibitors | PHKA1, PIK3CA, PHKA2 | MRGPRX4 2325/4885LMNA 3954/4885L3MBTL1 4738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.